Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Annals of Neurology

• Publication date

  1988-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/ana.410240417PMID 2977086
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Absence status epilepticus with computed tomographic brain changes following metrizamide myelography

  1988cited by this paper
• A Syndrome with Juvenile Cataract, Cerebellar Atrophy, Mental Retardation and Myopathy

  1987cited by this paper
• Increase in the Content of Quinolinic Acid in Cerebrospinal Fluid and Frontal Cortex of Patients with Hepatic Failure

  1986cited by this paper
• A radioenzymatic assay for quinolinic acid.

  1986cited by this paper
• [Muscle involvement in patients with Marinesco-Sjögren syndrome: with reference to clinical manifestations of adult patients].

  1985cited by this paper
• II: Excitotoxic models for neurodegenerative disorders

  1984cited by this paper
• Excitotoxic models for neurodegenerative disorders.

  1984cited by this paper
• Diagnostic needle muscle biopsy. A practical and reliable alternative to open biopsy.

  1984cited by this paper
• Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat.

  1984cited by this paper
• Sensorimotor neuropathy in a patient with Marinesco-Sjögren syndrome.

  1983cited by this paper
• Huntington disease

  1979cited by this paper
• Cerebellar ataxia and hypergonadotropic hypogonadism in two kindreds. Chance concurrence, pleiotropism or linkage?

  1976cited by this paper
• Hereditary cerebellar ataxia associated with congenital cataracts. 4 cases of the Marinesco-Sjögren syndrome with some unusual features.

  1972cited by this paper
• Marinesco-Sjögren syndrome. Report of an autopsy.

  1972cited by this paper
• Marinesco-Sjögren-Garland syndrome with unusual features.

  1971cited by this paper
• The Marinesco-Sjogren syndrome. Hereditary cerebello-lental degeneration with mental retardation.

  1968cited by this paper
• Marinesco‐Sjögren Syndrome: Spinocerebellar Ataxia, Congenital Cataract, Somatic and Mental Retardation

  1965cited by this paper
• HEREDITARY CONGENITAL SPINOCEREBELLAR ATAXIA COMBINED WITH CONGENITAL CATARACT AND OLIGOPHRENIA

  1947cited by this paper

• Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities

  2024cites this paper
• Lack of Evidence for Kynurenine Pathway Dysfunction in Huntington’s Disease: CSF and Plasma Analyses from the HDClarity Study

  2024cites this paper
• Development of biofluid biomarkers for Huntington’s disease

  2020cites this paper
• Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease

  2020cites this paper
• Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment

  2019cites this paper
• Biofluid Biomarkers in Huntington's Disease.

  2018cites this paper
• Huntington’s Disease

  2018cites this paper
• Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research.

  2018cites this paper
• A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward

  2018cites this paper
• Huntington’s Disease

  2017cites this paper
• Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects

  2017cites this paper
• Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions.

  2017cites this paper
• Cerebrospinal Fluid Biomarkers for Huntington’s Disease

  2016cites this paper
• Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice

  2016cites this paper
• Tryptophan Metabolism in Rat Liver After Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors

  2016cites this paper
• Human 3-hydroxyanthranilate 3,4-dioxygenase () dynamics and reaction, a multilevel computational study.

  2015cites this paper
• Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases

  2015cites this paper
• The Role of Kynurenine Pathway Metabolites in Neuropsychiatric Disorders

  2015cites this paper
• Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology

  2015cites this paper
• Dysregulation of the kynurenine pathway in psychotic disorders : immunological aspects

  2014influential citation
• Global identification of O‐GlcNAc transferase (OGT) interactors by a human proteome microarray and the construction of an OGT interactome

  2014cites this paper
• Imbalanced Kynurenine Pathway in Schizophrenia

  2014cites this paper
• Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway.

  2014cites this paper
• Inflammatory Mediators as Biomarkers in Brain Disorders

  2013cites this paper
• Huntington’s disease

  2013cites this paper
• Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

  2012cites this paper
• The Spinal Actions of Nonsteroidal Anti-Inflammatory Drugs and the Dissociation between their Anti-Inflammatory and Analgesic Effects

  2012cites this paper
• Protective compounds in animal models of trigeminal activation and neurodegeneration.

  2012cites this paper
• Pharmacology of Endogenous Neurotoxins

  2012cites this paper
• Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

  2010cites this paper
• Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

  2010cites this paper
• Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder

  2010cites this paper
• 13.12 – Glial Cells*

  2010cites this paper
• Characterization of the CAG 140 Mouse Model of Huntington's Disease and the Effects of rAAV Delivered shRNA and hGFP

  2010cites this paper
• Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats.

  2010cites this paper
• Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.

  2010cites this paper
• The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.

  2009cites this paper
• Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease

  2009cites this paper
• Crystal structure of bovine 3‐hydroxyanthranilate 3,4‐dioxygenase

  2009cites this paper
• Protective compounds in animal models of trigeminal activation and neurodegeneration

  2009cites this paper
• 5 Kynurenines in the Brain: Preclinical and Clinical Studies, Therapeutic Considerations

  2009cites this paper
• Beyond the Basal Ganglia Widespread pathology in Huntington’s disease

  2008cites this paper
• Beyond the basal ganglia

  2008cites this paper
• Beyond the Basal Ganglia Widespread pathology in Huntington ’ s disease

  2008cites this paper
• Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.

  2008cites this paper
• Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.

  2007cites this paper
• AAV-vector mediated gene delivery for Huntington's Disease : an investigative therapeutic study.

  2007cites this paper
• Kynurenines in neurological disorders

  2007cites this paper
• In vitro effect of quinolinic acid on energy metabolism in brain of young rats.

  2007cites this paper
• ETUDE DE L'AMPLIFICATION DE LA NEURODEGENERESCENCE EXCITOTOXIQUE PAR UNE DYSFONCTION MITOCHONDRIALE : IMPLICATIONS POUR LA MALADIE DE HUNTINGTON

  2006cites this paper
• Efeito in vitro de quinureninas sobre vários parâmetros de estresse oxidativo em córtex cerebral de ratos jovens

  2006cites this paper
• Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.

  2004cites this paper
• Kynurenines in neurodegenerative disorders: therapeutic consideration.

  2004cites this paper
• Rapid appearance of β-amyloid precursor protein immunoreactivity in glial cells follwing excitotoxic brain injury

  2004cites this paper
• Alcohol, nutrition, and recovery of brain function.

  2004cites this paper
• Huntington’s disease

  2003cites this paper
• Huntington's disease.

  2003cites this paper
• Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

  2001influential citation
• Increased cortical kynurenate content in schizophrenia.

  2001cites this paper
• The role of kynurenines in the production of neuronal death, and the neuroprotective effect of purines

  2001cites this paper
• Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.

  2001influential citation
• Neopterin Production and Tryptophan Degradation in Patients with Neurodegenerative Diseases: Link between Immune Activation and Neuropsychiatric Symptoms

  2001cites this paper
• Endogenous neurotoxins from tryptophan.

  2001cites this paper
• Malonic Acid and the Chronic Administration Model of Excitotoxicity

  2000cites this paper
• Degradation of tryptophan in neurodegenerative disorders.

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats

  1999cites this paper
• Activated Immune System in Patients with Huntington's Disease

  1998cites this paper
• pros-Methylimidazoleacetic Acid: A Potential Neurotoxin in Brain?

  1998cites this paper
• Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.

  1997cites this paper
• Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids.

  1996cites this paper
• Synergistic effects of chronic exposure to subthreshold concentrations of quinolinic acid and malonate in the rat striatum.

  1996cites this paper
• Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations.

  1996cites this paper
• Hypoxia, excitotoxicity, and neuroprotection in the hippocampal slice preparation.

  1995cites this paper
• Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.

  1995cites this paper
• Non-steroidal anti-inflammatory drugs and spinal nociceptive processing

  1995cites this paper
• Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

  1995cites this paper
• 3-Hydroxyanthranilic acid oxygenase-containing astrocytic processes surround glutamate-containing axon terminals in the rat striatum

  1995cites this paper
• Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.

  1995cites this paper
• Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

  1995cites this paper
• The 1993 Upjohn Award Lecture. Quinolinic acid induced brain neurotransmitter deficits: modulation by endogenous excitotoxin antagonists.

  1994cites this paper
• Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

  1994cites this paper
• Quinolinic acid in neurological disease: opportunities for novel drug discovery.

  1994cites this paper
• Therapeutische Ansätze zur neurodegenerativen Protektion

  1994cites this paper
• Non-steroidal anti-inflammatory drugs and spinal nociceptive processing

  1994cites this paper
• Neuronal Plasticity: A Potential Role in Spiny Striatal Neuron Degeneration in Huntington's Disease

  1994cites this paper
• Contributory mechanisms in the causation of neurodegenerative disorders.

  1993cites this paper
• Quinolinic Acid and Inflammation

  1993cites this paper
• Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro.

  1993cites this paper
• Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid.

  1993cites this paper
• Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration.

  1993cites this paper
• Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.

  1993cites this paper
• Mechanism of Delayed Increases in Kynurenine Pathway Metabolism in Damaged Brain Regions Following Transient Cerebral Ischemia

  1993cites this paper
• Oxidative stress in some dementia types.

  1993cites this paper
• A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

  1993cites this paper
• Neuropharmacology of quinolinic and kynurenic acids.

  1993cites this paper
• Kynurenine Pathway Enzymes in Brain: Responses to Ischemic Brain Injury Versus Systemic Immune Activation

  1993cites this paper
• Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid.

  1992cites this paper
• Alternative excitotoxic hypotheses

  1992cites this paper